Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Ramanathan

Showing results (281-290 of 302) with videos related to

Pageof 31
Sort By:
Cancer Chemotherapy and Pharmacology|April 12, 2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyTiciana B Leal, Scot C Remick, Chris H Takimoto, et al.
Journal of the American College of Cardiology|July 14, 2001
Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME)D A Morrison, G Sethi, J Sacks, et al.
Clinical Colorectal Cancer|March 18, 2021
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I InhibitorsKoji Ando, Al Ozonoff, Shin-Yin Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2016
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomasA Patnaik, L J Appleman, A W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2013
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancerColin D Weekes, Daniel D Von Hoff, Alex A Adjei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupJoseph Gibbons, Merrill J Egorin, Ramesh K Ramanathan, et al.
Plos One|February 4, 2014
Integrated genomic and epigenomic analysis of breast cancer brain metastasisBodour Salhia, Jeff Kiefer, Julianna T D Ross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07J Philip Kuebler, H Samuel Wieand, Michael J O'Connell, et al.
The New England Journal of Medicine|October 18, 2013
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineDaniel D Von Hoff, Thomas Ervin, Francis P Arena, et al.
Investigational New Drugs|February 12, 2013
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignanciesGlen J Weiss, Joseph Chao, Jeffrey D Neidhart, et al.
Pageof 31

Showing results (281-290 of 302) with videos related to

Sort By:
Pageof 31
Cancer Chemotherapy and Pharmacology|April 12, 2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyTiciana B Leal, Scot C Remick, Chris H Takimoto, et al.
Journal of the American College of Cardiology|July 14, 2001
Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME)D A Morrison, G Sethi, J Sacks, et al.
Clinical Colorectal Cancer|March 18, 2021
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I InhibitorsKoji Ando, Al Ozonoff, Shin-Yin Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2016
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomasA Patnaik, L J Appleman, A W Tolcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2013
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancerColin D Weekes, Daniel D Von Hoff, Alex A Adjei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working GroupJoseph Gibbons, Merrill J Egorin, Ramesh K Ramanathan, et al.
Plos One|February 4, 2014
Integrated genomic and epigenomic analysis of breast cancer brain metastasisBodour Salhia, Jeff Kiefer, Julianna T D Ross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07J Philip Kuebler, H Samuel Wieand, Michael J O'Connell, et al.
The New England Journal of Medicine|October 18, 2013
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineDaniel D Von Hoff, Thomas Ervin, Francis P Arena, et al.
Investigational New Drugs|February 12, 2013
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignanciesGlen J Weiss, Joseph Chao, Jeffrey D Neidhart, et al.
Pageof 31